TIDMERGO

RNS Number : 8557O

Ergomed plc

01 February 2019

PRESS RELEASE

FOR IMMEDIATE RELEASE

Exercise of Options and Issue of Equity

Guildford, UK - 1 February 2019: Ergomed plc (LSE: ERGO) ('Ergomed' or 'the Company'), a company focused on providing specialised services to the pharmaceutical industry, has issued and allotted 1,000,000 new ordinary shares of 1p each in the Company ("New Ordinary Shares") following the exercise by a former employee of options awarded under the Company's Unapproved Executive Share Option Scheme 2007.

Accordingly, an application has been made for the 1,000,000 New Ordinary Shares to be admitted to trading on AIM ('Admission'). It is expected that Admission will occur at 8:00 a.m. on 5 February 2019. The New Ordinary Shares will rank pari passu with the existing ordinary shares in the Company.

Following Admission, the Company's enlarged issued share capital will comprise 46,016,438 ordinary shares with one voting right per share. No shares are held in Treasury. The total number of voting rights in the Company is therefore 46,016,438.

This figure of 46,016,438 ordinary shares may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.

- Ends -

Enquiries:

 
 Ergomed plc                                           Tel: +44 (0) 1483 503205 
 Dr Miroslav Reljanovic (Executive Chairman) 
 Stuart Jackson (Chief Financial Officer) 
 
 Numis Securities Limited                             Tel: +44 (0) 20 7260 1000 
 Michael Meade / Freddie Barnfield (Nominated 
  Adviser) 
 James Black (Broker) 
 
 Consilium Strategic Communications - for             Tel: +44 (0) 20 3709 5700 
  UK enquiries 
 Chris Gardner / Mary-Jane Elliott                  ergomed@consilium-comms.com 
 Matthew Neal / Olivia Manser 
 
 MC Services - for Continental European enquiries        Tel: +49 211 5292 5222 
 Anne Hennecke

About Ergomed plc

Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing, profitable services offering encompasses a complete suite of specialist pharmacovigilance solutions, integrated under the PrimeVigilance brand, in addition to a full range of high quality contract research and trial management services (CRO). Leveraging its CRO expertise, Ergomed also has a drug development portfolio of co-development partnerships and wholly-owned programmes. For further information, visit: http://ergomedplc.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

IOEEAFAFEDENEFF

(END) Dow Jones Newswires

February 01, 2019 06:31 ET (11:31 GMT)

Ergomed (LSE:ERGO)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Ergomed Charts.
Ergomed (LSE:ERGO)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Ergomed Charts.